ArticleACS chemical biology2019
Molecular Determinants of the Intrinsic Efficacy of the Antipsychotic Aripiprazole.
Article in ACS chemical biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 25 citations in OpenAlex.
- The structure of the dopamine DScience advances · 2026Article
- Tailoring cariprazine for dual disorders via secondary pharmacophore optimization.European journal of medicinal chemistry · 2026Article
- Partial agonist antipsychotic drugs differentially interact with a secondary binding site at the dopamine D2 receptor.The international journal of neuropsychopharmacology · 2025Article
- Identification of a Lipid-Exposed Extrahelical Binding Site for Positive Allosteric Modulators of the Dopamine DACS chemical neuroscience · 2025Article
- Unraveling Activation-Related Rearrangements and Intrinsic Divergence from Ligand-Specific Conformational Changes of the Dopamine D3 and D2 Receptors.Journal of chemical information and modeling · 2024Review
- Unraveling activation-related rearrangements and intrinsic divergence from ligand-induced conformational changes of the dopamine D3 and D2 receptors.bioRxiv : the preprint server for biology · 2023Article
- Dopamine DJournal of medicinal chemistry · 2023Article
- Identification and Characterization of ML321: A Novel and Highly Selective DACS pharmacology & translational science · 2023Article
- Approach to the specificity and selectivity between D2 and D3 receptors by mutagenesis and binding experiments part I: Expression and characterization of D2 and D3 receptor mutants.Protein science : a publication of the Protein Society · 2022Article
- Ligand-directed bias of G protein signaling at the dopamine DCell chemical biology · 2022Article
- Structure-based design of a novel third-generation antipsychotic drug lead with potential antidepressant properties.Nature neuroscience · 2022Article
- Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine DFrontiers in psychiatry · 2022Review
- Structure Activity Relationships for a Series of Eticlopride-Based Dopamine DJournal of medicinal chemistry · 2021Article
- Pharmacological Characterization of the Imipridone Anticancer Drug ONC201 Reveals a Negative Allosteric Mechanism of Action at the DMolecular pharmacology · 2021Article
- Potent and Subtype-Selective Dopamine DJournal of medicinal chemistry · 2021Article
- Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders.Biomolecules · 2021Review
- Ligand with Two Modes of Interaction with the Dopamine DACS chemical neuroscience · 2020Article
- A structural basis for how ligand binding site changes can allosterically regulate GPCR signaling and engender functional selectivity.Science signaling · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 3 countries.
Funding
Abstract
Partial agonists of the dopamine D
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.